Imfinzi-based regimens deliver major survival gains in muscle-invasive bladder cancer
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
Subscribe To Our Newsletter & Stay Updated